Xubin Li

TL;DR: Using 16 key molecular features, five prognostic subtypes were identified and a decision tree that classified patients into the subtypes based on just six features that are assessable in clinical laboratories was developed, raising potential implications for immunotherapy.

TL;DR: Tumors with TP53 mutations differ from their non-mutated counterparts in RNA, miRNA, and protein expression patterns, with mutant TP53 tumors displaying enhanced expression of cell cycle progression genes and proteins.

TL;DR: An integromic analysis of gene alterations that modulate transforming growth factor β-Smad-mediated signaling in 9,125 tumor samples across 33 cancer types in The Cancer Genome Atlas provides a broad molecular perspective relevant for future functional and therapeutic studies of the diverse cancer pathways mediated by the TGF-β superfamily.

TL;DR: It is observed that somatic mutations are associated with, but not definitive for, reduced MHC expression on FL cells and expression of MHC class II genes by FL cells was associated with significant differences in the proportions and targetable immunophenotypic characteristics of T-cells.